When and How Long to Treat Chronic Lymphocytic Leukemia?
Ibrutinib is an effective frontline therapy for chronic lymphocytic leukemia
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
- Milestones in Chronic Lymphocytic Leukemia
- Trial Results Show Majority of Patients With CLL Achieve uMRD With VenO
- On the architecture of translational research designed to control chronic lymphocytic leukemia
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)